Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 58
Summary
- Conditions
- Melanoma
- Metastatic Melanoma
- Mucosal Melanoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02126579
- Collaborators
- University of Virginia
- Investigators
- Principal Investigator: Craig L Slingluff, Jr., M.D. University of Virginia
Get Well Soon